Table 2

Effect of predictors on treatment with enoxaparin

Predictor(a) Time taken to achieve target anti-(factor Xa) (days)(b) Anti-(factor Xa) measurements within target range (%)(c) Anti-(factor Xa) measurements < target range (%)(d) Anti-(factor Xa) measurements > target range (%)(e) Mean number of dose changes/month
Data are reported as median (25th/75th centile). Significant relations are in bold.
AV, Assisted ventilation; CHD, congenital heart disease; NICU, neonatal intensive care unit; PT, prothrombin time; INR, international normalised ratio.
Gestational age (weeks)
    <37 weeks 6.0 (2.5/10.0) 50.0 (26.8/63.3) 50.0 (36.7/73.2) 0.0 (0.0/0.0)2.2 (1.3/3.7)
    ⩾37 weeks 2.0 (1.0/6.0) 52.3 (33.3/75.0) 44.5 (25.0/66.7) 0.0 (0.0/0.0)1.1 (0.8/2.0)
    p Value <0.001 NS <0.05 NSNS
AV/NICU
    AV + NICU2.0 (1.0/6.0)60.0 (37.2/75.0)40.0 (25.0/51.4)0.0 (0.0/0.0)1.7 (0.6/2.5)
    NICU2.0 (2.0/7.0)57.1 (33.3/75)42.9 (25.0/66.7)0.0 (0.0/0.0)1.7 (1.0/3.0)
    Standard care4.0 (1.0/10.5)40.0 (33.3/61.7)60.0 (38.3/66.7)0.0 (0.0/0.0)1.2 (0.6/2.3)
    p ValueNSNSNSNSNS
CHD
    CHD2.0 (1.0/7.0)50.0 (33.3/75.0)46.7 (25.0/66.7)0.0 (0.0/0.0)1.3 (0.7/2.4)
    Non-CHD4.0 (2.0/6.0)56.4 (32.5/65.6)43.7 (34.4/67.5)–2.0 (1.0/3.8)
    p ValueNSNSNSNSNS
Impaired renal/liver function
    Yes4.0 (1.0/10.3)57.8 (33.3/75.0)35.4 (25.0/58.3)0.0 (0.0/8.0) 3.0 (2.0/4.3)
    No2.0 (1.5/6.0)50.0 (33.3/75.0)50.0 (31.0/66.7)0.0 (0.0/0.0) 1.0 (0.6/2.0)
    p ValueNSNSNSNS <0.001
Thrombocytopenia
    ⩽120×109/l2.0 (1.0/6.5)50.0 (33.3/69.1)50.0 (29.7/66.7)0.0 (0.0/0.0)1.3 (0.8/2.7)
    >120×109/l2.5 (1.8/7.8)56.4 (33.3/75.0)41.4 (25.0/58.3)0.0 (0.0/0.0)1.7 (1.0/2.8)
    p ValueNSNSNSNSNS
Abnormal coagulation screening test (PT/INR)
    INR >1.52.5 (1.3/9.3)57.8 (27.8/72.9)42.2 (27.1/55.6)0.0 (0.0/0.0)1.9 (0.7/3.3)
    INR ⩽1.52.0 (1.0/6.0)50.0 (33.3/71.4)46.7 (27.3/66.7)0.0 (0.0/0.0)1.3 (1.0/2.8)
    p ValueNSNSNSNSNS